Ham Young Yoon, Lewis James S, Thompson George R
Department of Pharmacy, Oregon Health & Science University, Portland, OR 97239, USA.
Department of Internal Medicine Division of Infectious Diseases & Department of Medical Microbiology & Immunology; University of California Davis Medical Center, Sacramento, CA 95817, USA.
Future Microbiol. 2021 Jan;16(1):27-36. doi: 10.2217/fmb-2020-0217.
Rezafungin is a novel echinocandin with exceptional stability and solubility and a uniquely long half-life allowing for front-loaded drug exposure with once-weekly dosing. Rezafungin has been shown comparable to other echinocandins, with activity against spp. and spp. including subsets of echinocandin-resistant and azole-resistant isolates. Available clinical data show robust safety and promising efficacy. Phase III trials will provide data on efficacy of rezafungin for the treatment of candidemia and invasive candidiasis and for the prevention of invasive fungal disease in blood and bone marrow transplant recipients. Rezafungin is a promising new candidate in the antifungal arsenal that opens up clinical possibilities based on its impressive half-life, such as early hospital discharge for stable patients and use as prophylaxis in immunocompromised patients.
瑞扎芬净是一种新型棘白菌素，具有卓越的稳定性和溶解性，半衰期独特地长，允许通过每周一次给药实现前期负荷药物暴露。已证明瑞扎芬净与其他棘白菌素相当，对 属和 属具有活性，包括对棘白菌素耐药和唑类耐药的分离株亚群。现有的临床数据显示出强大的安全性和有前景的疗效。III期试验将提供关于瑞扎芬净治疗念珠菌血症和侵袭性念珠菌病以及预防血液和骨髓移植受者侵袭性真菌病疗效的数据。瑞扎芬净是抗真菌药物库中一个有前景的新候选药物，基于其令人印象深刻的半衰期开辟了临床可能性，例如让病情稳定的患者提前出院以及用作免疫功能低下患者的预防用药。
